

16.2.3 Participants Excluded From the Efficacy Analysis

[Listing 16.2.3.1](#) [Analysis Sets 1 Randomized Set](#)

[Listing 16.2.3.2](#) [Analysis Sets 2 Randomized Set](#)

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011030	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011042	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2011043	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011056	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011057	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011060	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011064	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011067	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011068	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011069	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011070	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011086	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011088	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021061	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021062	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021073	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021078	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021082	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021089	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Reason	First Injection	Second Injection	Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021094	Yes	Yes	No/Did not receive Vaccination #2	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021096	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021107	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021111	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021135	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021137	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Post-baseline COVID-19 infection prior to the visit	No/Serum collection out of window; Other study deviation	No/Post-baseline COVID-19 infection prior to the visit	No/Serum collection out of window; Other study deviation
US2021138	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021144	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Other study deviation	Yes	No/Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021155	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021161	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021162	Yes	Yes	No/Did not receive Vaccination #2	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021175	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031001	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031009	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031014	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031022	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031023	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031029	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031038	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031040	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031041	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031043	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason	First Injection	Second Injection	Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
					Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
					Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2031045	Yes	Yes	No/Did not receive Vaccination #2	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2031048	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031049	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2031058	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031071	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031074	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031081	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Post-baseline COVID-19 infection prior to the visit	Yes	No/Post-baseline COVID-19 infection prior to the visit
US2041005	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041011	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2041014	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041019	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2041020	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041022	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041025	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041029	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041034	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041042	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

				Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Solicited Safety Set/ Exclusion Reason		Binding Antibody		Neutralizing Antibody [1]		Binding Antibody	
Subject ID	Safety Set/ Exclusion Criteria	First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041043	Yes	Yes	No/Did not receive Vaccination #2	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2041056	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	First Injection	Second Injection	Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Solicited Safety Set/ Exclusion Reason		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041059	Yes	Yes	No/Did not receive Vaccination #2	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041062	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041078	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041086	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041089	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041090	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051022	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051035	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2051036	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051044	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2061003	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061015	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2061018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061021	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061022	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061025	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Dosing error	No/Dosing error	No/Dosing error	No/Dosing error
US2061032	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071012	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071014	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071017	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Other study deviation	No/Serum collection out of window; Other study deviation	No/Other study deviation	No/Serum collection out of window; Other study deviation
US2071022	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071042	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071044	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071046	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071049	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071050	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071059	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071062	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071064	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071066	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071070	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071072	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081026	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081033	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081038	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081042	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081046	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081049	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081057	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081058	Yes	Yes	No/Did not receive Vaccination #2	Yes	Yes	Yes	Yes	No/Did not receive Vaccination #2; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011020	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011029	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011048	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011051	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2011055	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011061	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011084	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011087	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011090	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011091	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011092	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2011093	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011095	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2011102	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021058	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021064	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021084	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021090	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021147	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021166	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021167	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021179	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031002	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031004	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031011	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031016	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031030	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031042	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031051	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031056	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2031057	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031063	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031066	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031072	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031080	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041002	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041003	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041006	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041007	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041012	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041013	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041016	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2041023	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041027	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041030	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041036	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041047	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Post-baseline COVID-19 infection prior to the visit	Yes	No/Post-baseline COVID-19 infection prior to the visit
US2041049	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2041051	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041053	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	First Injection	Second Injection	Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Solicited Safety Set/ Exclusion Reason		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041055	Yes	Yes	No/Did not receive Vaccination #2	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	First Injection	Second Injection	Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Solicited Safety Set/ Exclusion Reason		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041058	Yes	Yes	No/Did not receive Vaccination #2	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041064	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Serum collection out of immunogenicity result at study deviation	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation	No/Vaccination #2 out of window; Serum collection out of immunogenicity result at study deviation	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2041071	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041075	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041076	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041077	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041088	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041091	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041092	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2051008	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051009	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051010	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051011	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2051018	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051027	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2051031	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051032	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051033	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2051034	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051038	Yes	Yes	No/Did not receive Vaccination #2	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit
US2051040	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051042	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2051043	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051048	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051050	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2061001	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2061006	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061009	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061011	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061013	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061019	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2061026	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071001	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071003	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071004	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071029	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071030	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2071032	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071033	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Other study deviation	No/Other study deviation	No/Other study deviation	No/Other study deviation
US2071063	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071067	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2071074	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071081	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081036	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081039	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081041	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081052	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081054	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081059	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011019	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011039	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011041	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011046	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011050	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011059	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011065	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011080	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2011085	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011089	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011103	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021059	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2021063	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021067	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021068	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021074	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021080	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021093	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021099	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021101	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021121	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021145	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021151	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021154	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021164	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021180	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021182	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2031012	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2031013	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031019	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2031020	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031021	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031026	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031027	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031033	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031035	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031037	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031047	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031050	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031060	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031062	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2031073	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031079	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031084	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041008	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2041010	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041024	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041026	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041041	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041046	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041048	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041060	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2041061	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2041073	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041079	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041080	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041084	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051001	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051002	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051003	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051012	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051013	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051017	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2051019	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051020	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051024	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/Serum collection out of window; Other study deviation	No/There was no immunogenicity result at corresponding visit	No/Serum collection out of window; Other study deviation
US2051025	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2051026	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

				Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Solicited Safety Set/ Exclusion Reason		Binding Antibody		Neutralizing Antibody [1]		Binding Antibody	
Subject ID	Safety Set/ Exclusion Criteria	First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051028	Yes	Yes	No/Did not receive Vaccination #2	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051029	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2051030	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051045	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061008	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061010	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061020	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2061023	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2061024	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Dosing error	No/Dosing error	No/Dosing error	No/Dosing error
US2061027	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071002	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071016	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Reason	Full Analysis Set/Exclusion Reason						Per-Protocol Set/Exclusion Reason			
		Solicited Safety Set/ Exclusion Reason		Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071026	Yes	Yes	Yes	No/There was no immunogenicity result at baseline	No/There was no immunogenicity result at baseline	Yes	Yes	No/Not in Full Analysis Set; Other study deviation	No/Not in Full Analysis Set; Other study deviation	No/Other study deviation	No/Other study deviation
US2071036	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071038	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071039	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2071040	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071051	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071068	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071069	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071071	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071073	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071077	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081023	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081025	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081028	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081045	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081051	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081062	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081063	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

				Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		Solicited Safety Set/Exclusion Reason		Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
Subject ID	Safety Set/Exclusion Criteria	First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081064	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011007	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011011	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011023	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011109	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011114	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011116	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011120	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011124	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011126	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011130	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011131	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011142	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011145	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011152	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at baseline and corresponding visit	No/There was no immunogenicity result at baseline and corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2011155	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011156	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at baseline and corresponding visit	No/There was no immunogenicity result at baseline and corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2011157	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021015	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021021	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021022	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021043	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021130	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021185	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021189	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021196	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021198	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021206	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021207	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2021219	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021222	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2031085	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031089	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031092	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031095	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031098	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031100	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2031102	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Post-baseline COVID-19 infection prior to the visit	Yes	No/Post-baseline COVID-19 infection prior to the visit
US2031103	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031110	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031116	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031124	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031125	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031129	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031131	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason					
		Solicited Safety Set/ Exclusion Reason		Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041102	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at baseline and corresponding visit	No/There was no immunogenicity result at baseline and corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041114	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2041115	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041121	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041132	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041142	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041146	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041151	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041152	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041166	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051055	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051063	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051072	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit	Yes	No/Serum collection out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit
US2051073	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051086	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051087	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051089	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051098	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051112	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061035	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2061043	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061046	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2061051	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061055	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071005	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071041	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071084	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071085	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071086	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071088	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071092	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071094	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071098	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Other study deviation	No/Other study deviation	No/Other study deviation	No/Other study deviation
US2071100	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071102	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Reason	First Injection	Second Injection	Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071103	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at baseline and corresponding visit	No/There was no immunogenicity result at baseline and corresponding visit	Yes	No/Serum collection out of window; Other study deviation	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071105	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at baseline and corresponding visit	No/There was no immunogenicity result at baseline and corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2081004	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081005	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081007	Yes	No/Did not contribute any solicited AR data for Vaccination #1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081015	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081017	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081029	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081030	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081065	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081066	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081073	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081077	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081080	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081087	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081097	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081103	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081104	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081113	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081119	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2081125	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011012	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011014	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011032	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011040	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011117	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011123	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011125	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit
US2011127	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2011137	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011138	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2011153	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021004	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021012	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021019	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021020	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021045	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021047	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021133	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021190	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021192	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021205	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2021216	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021217	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2021220	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2021226	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2031086	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2031096	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031097	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031104	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031105	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031106	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2031107	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2031108	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031109	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031114	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2031121	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2031128	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041094	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041100	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

				Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Solicited Safety Set/ Exclusion Reason		Binding Antibody		Neutralizing Antibody [1]		Binding Antibody	
Subject ID	Safety Set/ Exclusion Criteria	First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041103	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at baseline and corresponding visit	No/There was no immunogenicity result at baseline and corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2041104	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041106	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041109	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041111	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041113	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041118	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041119	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041127	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2041130	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041139	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2041145	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041150	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041155	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2051057	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051059	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051060	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051066	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051068	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051071	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051078	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051081	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2051092	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051093	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051094	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051095	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2051096	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051099	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051100	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051103	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2051105	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051107	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051109	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2061037	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2061053	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2061057	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061064	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061068	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071007	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071024	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071025	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071083	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2071090	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

				Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		Solicited Safety Set/Exclusion Reason		Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
Subject ID	Safety Set/Exclusion Criteria	First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071099	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2071101	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071104	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071106	Yes	Yes	No/Did not receive Vaccination #2	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; Serum collection out of window; Post-base COVID-19 infection prior to the visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; Serum collection out of window; Post-base COVID-19 infection prior to the visit
US2081003	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081009	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081020	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081070	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2081071	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081085	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2081090	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081092	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081100	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at baseline	No/There was no immunogenicity result at baseline	Yes	No/Serum collection out of window; Other study deviation	No/Not in Full Analysis Set	No/Serum collection out of window; Not in Full Analysis Set; Other study deviation
US2081110	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081112	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2081118	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081123	Yes	Yes	No/Did not receive Vaccination #2	Yes	Yes	Yes	Yes	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011004	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011009	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011028	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011113	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at baseline	No/There was no immunogenicity result at baseline and corresponding visit	Yes	Yes	No/Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011118	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2011121	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011122	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011128	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011139	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2011149	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2011159	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2011162	Yes	Yes	Yes	No/There was no immunogenicity result at baseline	No/There was no immunogenicity result at baseline	No/There was no immunogenicity result at baseline	No/There was no immunogenicity result at baseline	No/Not in Full Analysis Set	No/Not in Full Analysis Set	No/Not in Full Analysis Set	No/Not in Full Analysis Set
US2021003	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021007	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021011	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021031	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021114	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021115	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021186	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021208	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2021211	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021214	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2021215	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/Serum collection out of window; Other study deviation	Yes	No/There was no immunogenicity result at corresponding visit; Other study deviation

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2021218	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021230	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021232	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2021234	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031091	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2031093	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031101	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2031111	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2031112	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2031122	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041096	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041107	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041108	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2041112	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041117	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041120	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041122	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2041123	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041125	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041126	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

				Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Solicited Safety Set/ Exclusion Reason		Binding Antibody		Neutralizing Antibody [1]		Binding Antibody	
Subject ID	Safety Set/ Exclusion Criteria	First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041131	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation
US2041136	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041138	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2041144	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2041149	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2051054	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051064	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051069	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051070	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051074	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2051075	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2051077	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051084	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		First Injection	Second Injection	Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
				Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051085	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051088	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	Yes	Yes	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/There was no immunogenicity result at corresponding visit; Not in Full Analysis Set

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051097	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2051101	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051102	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

				Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
		Solicited Safety Set/ Exclusion Reason		Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
Subject ID	Safety Set/ Exclusion Criteria	First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051104	Yes	Yes	No/Did not receive Vaccination #2	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2051106	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2051108	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2051111	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2061036	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2061045	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation	Yes	No/Serum collection out of window; Other study deviation
US2061063	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071006	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071013	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2071037	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071043	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071082	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071087	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071089	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071091	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2071093	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2071095	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2071096	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit; Other study deviation	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation
US2081001	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081002	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081014	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081016	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081019	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081035	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081069	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081072	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2081075	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081076	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2081081	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081088	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2081091	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2081093	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081099	Yes	Yes	Yes	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit	Yes	Yes	Yes	No/There was no immunogenicity result at corresponding visit
US2081108	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081116	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.1
Analysis Sets 1
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Safety Set/ Exclusion Criteria	Solicited Safety Set/ Exclusion Reason		Full Analysis Set/Exclusion Reason				Per-Protocol Set/Exclusion Reason			
				Binding Antibody		Neutralizing Antibody [1]		Binding Antibody		Neutralizing Antibody [1]	
		First Injection	Second Injection	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57	Day 29	Day 57
US2081117	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2081120	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081121	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
US2081129	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

[1] Based on samples from the First Lot.

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020301.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2011030	Yes	Yes	Yes	Yes
US2011042	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2011043	Yes	Yes	Yes	Yes
US2011056	Yes	Yes	Yes	Yes
US2011057	Yes	Yes	Yes	Yes
US2011060	Yes	Yes	Yes	Yes
US2011064	Yes	Yes	Yes	Yes
US2011067	Yes	Yes	Yes	Yes
US2011068	Yes	Yes	Yes	Yes
US2011069	Yes	Yes	Yes	Yes
US2011070	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2011086	Yes	Yes	Yes	Yes
US2011088	Yes	Yes	Yes	Yes
US2021061	Yes	Yes	Yes	Yes
US2021062	Yes	Yes	Yes	Yes
US2021073	Yes	Yes	Yes	Yes
US2021078	Yes	Yes	Yes	Yes
US2021082	Yes	Yes	Yes	Yes
US2021089	Yes	Yes	Yes	Yes
US2021094	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2021096	Yes	Yes	Yes	Yes
US2021107	Yes	Yes	Yes	Yes
US2021111	Yes	Yes	Yes	Yes
US2021135	Yes	Yes	Yes	Yes
US2021137	Yes	Yes	No/Post-baseline COVID-19 infection prior to the visit	No/Serum collection out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit
US2021138	Yes	Yes	Yes	Yes
US2021144	Yes	Yes	Yes	No/Other study deviation
US2021155	Yes	Yes	Yes	Yes
US2021161	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2021162	No/There was no immunogenicity result at corresponding visit	Yes	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation
US2021175	Yes	Yes	Yes	Yes
US2031001	Yes	Yes	Yes	Yes
US2031009	Yes	Yes	Yes	Yes
US2031014	Yes	Yes	Yes	Yes
US2031022	Yes	Yes	Yes	Yes
US2031023	Yes	Yes	Yes	Yes
US2031029	Yes	Yes	Yes	Yes
US2031038	Yes	Yes	Yes	Yes
US2031040	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2031041	Yes	Yes	Yes	Yes
US2031043	Yes	Yes	Yes	Yes
US2031045	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2031048	Yes	Yes	Yes	Yes
US2031049	Yes	Yes	Yes	Yes
US2031058	Yes	Yes	Yes	Yes
US2031071	Yes	Yes	Yes	Yes
US2031074	Yes	Yes	Yes	Yes
US2031081	Yes	Yes	Yes	No/Post-baseline COVID-19 infection prior to the visit

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041005	Yes	Yes	Yes	Yes
US2041011	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2041014	Yes	Yes	Yes	Yes
US2041019	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2041020	Yes	Yes	Yes	Yes
US2041022	Yes	Yes	Yes	Yes
US2041025	Yes	Yes	Yes	Yes
US2041029	Yes	Yes	Yes	Yes
US2041034	Yes	Yes	Yes	Yes
US2041042	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041043	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2041056	Yes	Yes	Yes	Yes
US2041059	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation
US2041062	Yes	Yes	Yes	Yes
US2041078	Yes	Yes	Yes	Yes
US2041086	Yes	Yes	Yes	Yes
US2041089	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041090	Yes	Yes	Yes	Yes
US2051022	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2051035	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2051036	Yes	Yes	Yes	Yes
US2051044	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2061003	Yes	Yes	Yes	Yes
US2061015	Yes	Yes	Yes	Yes
US2061018	Yes	Yes	Yes	Yes
US2061021	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2061022	Yes	Yes	Yes	Yes
US2061025	Yes	Yes	No/Dosing error	No/Dosing error
US2061032	Yes	Yes	Yes	Yes
US2071012	Yes	Yes	Yes	Yes
US2071014	Yes	Yes	Yes	Yes
US2071017	Yes	Yes	No/Other study deviation	No/Serum collection out of window; Other study deviation
US2071022	Yes	Yes	Yes	Yes
US2071042	Yes	Yes	Yes	Yes
US2071044	Yes	Yes	Yes	Yes
US2071046	Yes	Yes	Yes	Yes
US2071049	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2071050	Yes	Yes	Yes	Yes
US2071059	Yes	Yes	Yes	Yes
US2071062	Yes	Yes	Yes	Yes
US2071064	Yes	Yes	Yes	Yes
US2071066	Yes	Yes	Yes	Yes
US2071070	Yes	Yes	Yes	Yes
US2071072	Yes	Yes	Yes	Yes
US2081026	Yes	Yes	Yes	Yes
US2081033	Yes	Yes	Yes	Yes
US2081038	Yes	Yes	Yes	Yes
US2081042	Yes	Yes	Yes	Yes
US2081046	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2081049	Yes	Yes	Yes	Yes
US2081057	Yes	Yes	Yes	Yes
US2081058	Yes	Yes	No/Did not receive Vaccination #2; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2011020	Yes	Yes	Yes	Yes
US2011029	Yes	Yes	Yes	Yes
US2011048	Yes	Yes	Yes	Yes
US2011051	Yes	Yes	Yes	Yes
US2011055	Yes	Yes	Yes	Yes
US2011061	Yes	Yes	Yes	Yes
US2011084	Yes	Yes	Yes	Yes
US2011087	Yes	Yes	Yes	Yes
US2011090	Yes	Yes	Yes	Yes
US2011091	Yes	Yes	Yes	Yes
US2011092	Yes	Yes	Yes	Yes
US2011093	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2011095	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2011102	Yes	Yes	Yes	Yes
US2021058	Yes	Yes	Yes	Yes
US2021064	Yes	Yes	Yes	Yes
US2021084	Yes	Yes	Yes	Yes
US2021090	Yes	Yes	Yes	Yes
US2021147	Yes	Yes	Yes	Yes
US2021166	Yes	Yes	Yes	Yes
US2021167	Yes	Yes	Yes	Yes
US2021179	Yes	Yes	Yes	Yes
US2031002	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2031004	Yes	Yes	Yes	Yes
US2031011	Yes	Yes	Yes	Yes
US2031016	Yes	Yes	Yes	Yes
US2031030	Yes	Yes	Yes	Yes
US2031042	Yes	Yes	Yes	Yes
US2031051	Yes	Yes	Yes	Yes
US2031056	Yes	Yes	Yes	Yes
US2031057	Yes	Yes	Yes	Yes
US2031063	Yes	Yes	Yes	Yes
US2031066	Yes	Yes	Yes	Yes
US2031072	Yes	Yes	Yes	Yes
US2031080	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041002	Yes	Yes	Yes	Yes
US2041003	Yes	Yes	Yes	Yes
US2041006	Yes	Yes	Yes	Yes
US2041007	Yes	Yes	Yes	Yes
US2041012	Yes	Yes	Yes	Yes
US2041013	Yes	Yes	Yes	Yes
US2041016	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2041023	Yes	Yes	Yes	Yes
US2041027	Yes	Yes	Yes	Yes
US2041030	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041036	Yes	Yes	Yes	Yes
US2041047	Yes	Yes	Yes	No/Post-baseline COVID-19 infection prior to the visit
US2041049	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2041051	Yes	Yes	Yes	Yes
US2041053	Yes	Yes	Yes	Yes
US2041055	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041058	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set; Other study deviation
US2041064	Yes	No/There was no immunogenicity result at corresponding visit	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation
US2041071	Yes	Yes	Yes	Yes
US2041075	Yes	Yes	Yes	Yes
US2041076	Yes	Yes	Yes	Yes
US2041077	Yes	Yes	Yes	Yes
US2041088	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041091	Yes	Yes	Yes	Yes
US2041092	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2051008	Yes	Yes	Yes	Yes
US2051009	Yes	Yes	Yes	Yes
US2051010	Yes	Yes	Yes	Yes
US2051011	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2051018	Yes	Yes	Yes	Yes
US2051027	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2051031	Yes	Yes	Yes	Yes
US2051032	Yes	Yes	Yes	Yes
US2051033	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2051034	Yes	Yes	Yes	Yes
US2051038	Yes	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit
US2051040	Yes	Yes	Yes	Yes
US2051042	Yes	Yes	Yes	Yes
US2051043	Yes	Yes	Yes	Yes
US2051048	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2051050	Yes	Yes	Yes	Yes
US2061001	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2061006	Yes	Yes	Yes	Yes
US2061009	Yes	Yes	Yes	Yes
US2061011	Yes	Yes	Yes	Yes
US2061013	Yes	Yes	Yes	Yes
US2061019	Yes	Yes	Yes	Yes
US2061026	Yes	Yes	Yes	Yes
US2071001	Yes	Yes	Yes	Yes
US2071003	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2071004	Yes	Yes	Yes	Yes
US2071029	Yes	No/There was no immunogenicity result at corresponding visit	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation
US2071030	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2071032	Yes	Yes	Yes	Yes
US2071033	Yes	Yes	No/Other study deviation	No/Other study deviation
US2071063	Yes	Yes	Yes	Yes
US2071067	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2071074	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2071081	Yes	Yes	Yes	Yes
US2081036	Yes	Yes	Yes	Yes
US2081039	Yes	Yes	Yes	Yes
US2081041	Yes	Yes	Yes	Yes
US2081052	Yes	Yes	Yes	Yes
US2081054	Yes	Yes	Yes	Yes
US2081059	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2011018	Yes	Yes	Yes	Yes
US2011019	Yes	Yes	Yes	Yes
US2011039	Yes	Yes	Yes	Yes
US2011041	Yes	Yes	Yes	Yes
US2011046	Yes	Yes	Yes	Yes
US2011050	Yes	Yes	Yes	Yes
US2011059	Yes	Yes	Yes	Yes
US2011065	Yes	Yes	Yes	Yes
US2011080	Yes	Yes	Yes	Yes
US2011085	Yes	Yes	Yes	Yes
US2011089	Yes	Yes	Yes	Yes
US2011103	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2021059	Yes	Yes	Yes	Yes
US2021063	Yes	Yes	Yes	Yes
US2021067	Yes	Yes	Yes	Yes
US2021068	Yes	Yes	Yes	Yes
US2021074	Yes	Yes	Yes	Yes
US2021080	Yes	Yes	Yes	Yes
US2021093	Yes	Yes	Yes	Yes
US2021099	Yes	Yes	Yes	Yes
US2021101	Yes	Yes	Yes	Yes
US2021121	Yes	Yes	Yes	Yes
US2021145	Yes	Yes	Yes	Yes
US2021151	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2021154	Yes	Yes	Yes	Yes
US2021164	Yes	Yes	Yes	Yes
US2021180	Yes	Yes	Yes	Yes
US2021182	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2031012	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2031013	Yes	Yes	Yes	Yes
US2031019	Yes	Yes	Yes	Yes
US2031020	Yes	Yes	Yes	Yes
US2031021	Yes	Yes	Yes	Yes
US2031026	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2031027	Yes	Yes	Yes	Yes
US2031033	Yes	Yes	Yes	Yes
US2031035	Yes	Yes	Yes	Yes
US2031037	Yes	Yes	Yes	Yes
US2031047	Yes	Yes	Yes	Yes
US2031050	Yes	Yes	Yes	Yes
US2031060	Yes	Yes	Yes	Yes
US2031062	Yes	Yes	Yes	Yes
US2031073	Yes	Yes	Yes	Yes
US2031079	Yes	Yes	Yes	Yes
US2031084	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041008	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2041010	Yes	Yes	Yes	Yes
US2041024	Yes	Yes	Yes	Yes
US2041026	Yes	Yes	Yes	Yes
US2041041	Yes	Yes	Yes	Yes
US2041046	Yes	Yes	Yes	Yes
US2041048	Yes	Yes	Yes	Yes
US2041060	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2041061	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041073	Yes	Yes	Yes	Yes
US2041079	Yes	Yes	Yes	Yes
US2041080	Yes	Yes	Yes	Yes
US2041084	Yes	Yes	Yes	Yes
US2051001	Yes	Yes	Yes	Yes
US2051002	Yes	Yes	Yes	Yes
US2051003	Yes	Yes	Yes	Yes
US2051012	Yes	Yes	Yes	Yes
US2051013	Yes	Yes	Yes	Yes
US2051017	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2051019	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2051020	Yes	Yes	Yes	Yes
US2051024	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	No/Serum collection out of window; Other study deviation
US2051025	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2051026	Yes	Yes	Yes	Yes
US2051028	Yes	Yes	No/Did not receive Vaccination #2; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation
US2051029	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2051030	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2051045	Yes	Yes	Yes	Yes
US2061008	Yes	Yes	Yes	Yes
US2061010	Yes	Yes	Yes	Yes
US2061020	Yes	Yes	Yes	Yes
US2061023	Yes	Yes	Yes	Yes
US2061024	Yes	Yes	No/Dosing error	No/Dosing error
US2061027	Yes	Yes	Yes	Yes
US2071002	Yes	Yes	Yes	Yes
US2071016	Yes	Yes	Yes	Yes
US2071026	Yes	Yes	No/Other study deviation	No/Other study deviation
US2071036	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2071038	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2071039	No/There was no immunogenicity result at corresponding visit	Yes	No/Vaccination #2 out of window; There was no immunogenicity result at corresponding visit; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2071040	Yes	Yes	Yes	Yes
US2071051	Yes	Yes	Yes	Yes
US2071068	Yes	Yes	Yes	Yes
US2071069	Yes	Yes	Yes	Yes
US2071071	Yes	Yes	Yes	Yes
US2071073	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 1 (Age >= 18 and age < 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2071077	Yes	Yes	Yes	Yes
US2081023	Yes	Yes	Yes	Yes
US2081025	Yes	Yes	Yes	Yes
US2081028	Yes	Yes	Yes	Yes
US2081045	Yes	Yes	Yes	Yes
US2081051	Yes	Yes	Yes	Yes
US2081062	Yes	Yes	Yes	Yes
US2081063	Yes	Yes	Yes	Yes
US2081064	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2011007	Yes	Yes	Yes	Yes
US2011011	Yes	Yes	Yes	Yes
US2011023	Yes	Yes	Yes	Yes
US2011109	Yes	Yes	Yes	Yes
US2011114	Yes	Yes	Yes	Yes
US2011116	Yes	Yes	Yes	Yes
US2011120	Yes	Yes	Yes	Yes
US2011124	Yes	Yes	Yes	Yes
US2011126	Yes	Yes	Yes	Yes
US2011130	Yes	Yes	Yes	Yes
US2011131	Yes	Yes	Yes	Yes
US2011142	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2011145	Yes	Yes	Yes	Yes
US2011152	Yes	Yes	Yes	Yes
US2011155	Yes	Yes	Yes	Yes
US2011156	Yes	Yes	Yes	Yes
US2011157	Yes	Yes	Yes	Yes
US2021015	Yes	Yes	Yes	Yes
US2021021	Yes	Yes	Yes	Yes
US2021022	Yes	Yes	Yes	Yes
US2021043	Yes	Yes	Yes	Yes
US2021130	Yes	Yes	Yes	Yes
US2021185	Yes	Yes	Yes	Yes
US2021189	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2021196	Yes	Yes	Yes	Yes
US2021198	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2021206	Yes	Yes	Yes	Yes
US2021207	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2021219	Yes	Yes	Yes	Yes
US2021222	Yes	Yes	Yes	Yes
US2031085	Yes	Yes	Yes	Yes
US2031089	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2031092	Yes	Yes	Yes	Yes
US2031095	Yes	Yes	Yes	Yes
US2031098	Yes	Yes	Yes	Yes
US2031100	Yes	Yes	Yes	Yes
US2031102	Yes	Yes	Yes	No/Post-baseline COVID-19 infection prior to the visit
US2031103	Yes	Yes	Yes	Yes
US2031110	Yes	Yes	Yes	Yes
US2031116	Yes	Yes	Yes	Yes
US2031124	Yes	Yes	Yes	Yes
US2031125	Yes	Yes	Yes	Yes
US2031129	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2031131	Yes	Yes	Yes	Yes
US2041102	Yes	Yes	Yes	Yes
US2041114	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2041115	Yes	Yes	Yes	Yes
US2041121	Yes	Yes	Yes	Yes
US2041132	Yes	Yes	Yes	Yes
US2041142	Yes	Yes	Yes	Yes
US2041146	Yes	Yes	Yes	Yes
US2041151	Yes	Yes	Yes	Yes
US2041152	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041166	Yes	Yes	Yes	Yes
US2051055	Yes	Yes	Yes	Yes
US2051063	Yes	Yes	Yes	Yes
US2051072	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation; Post-baseline COVID-19 infection prior to the visit
US2051073	Yes	Yes	Yes	Yes
US2051086	Yes	Yes	Yes	Yes
US2051087	Yes	Yes	Yes	Yes
US2051089	Yes	Yes	Yes	Yes
US2051098	Yes	Yes	Yes	Yes
US2051112	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2061035	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2061043	Yes	Yes	Yes	Yes
US2061046	Yes	Yes	Yes	Yes
US2061051	Yes	Yes	Yes	Yes
US2061055	Yes	Yes	Yes	Yes
US2071005	Yes	Yes	Yes	Yes
US2071041	Yes	Yes	Yes	Yes
US2071084	Yes	Yes	Yes	Yes
US2071085	Yes	Yes	Yes	Yes
US2071086	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2071088	Yes	Yes	Yes	Yes
US2071092	Yes	Yes	Yes	Yes
US2071094	Yes	Yes	Yes	Yes
US2071098	Yes	Yes	No/Other study deviation	No/Other study deviation
US2071100	Yes	Yes	Yes	Yes
US2071102	Yes	Yes	Yes	Yes
US2071103	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2071105	Yes	Yes	Yes	Yes
US2081004	Yes	Yes	Yes	Yes
US2081005	Yes	Yes	Yes	Yes
US2081007	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2081015	Yes	Yes	Yes	Yes
US2081017	Yes	Yes	Yes	Yes
US2081029	Yes	Yes	Yes	Yes
US2081030	Yes	Yes	Yes	Yes
US2081065	Yes	Yes	Yes	Yes
US2081066	Yes	Yes	Yes	Yes
US2081073	Yes	Yes	Yes	Yes
US2081077	Yes	Yes	Yes	Yes
US2081080	Yes	Yes	Yes	Yes
US2081087	Yes	Yes	Yes	Yes
US2081097	Yes	Yes	Yes	Yes
US2081103	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: Placebo

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2081104	Yes	Yes	Yes	Yes
US2081113	Yes	Yes	Yes	Yes
US2081119	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2081125	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2011012	Yes	Yes	Yes	Yes
US2011014	Yes	Yes	Yes	Yes
US2011032	Yes	Yes	Yes	Yes
US2011040	Yes	Yes	Yes	Yes
US2011117	Yes	Yes	Yes	Yes
US2011123	Yes	Yes	Yes	Yes
US2011125	Yes	Yes	Yes	Yes
US2011127	Yes	Yes	Yes	Yes
US2011137	Yes	Yes	Yes	Yes
US2011138	Yes	Yes	Yes	Yes
US2011153	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2021004	Yes	Yes	Yes	Yes
US2021012	Yes	Yes	Yes	Yes
US2021018	Yes	Yes	Yes	Yes
US2021019	Yes	Yes	Yes	Yes
US2021020	Yes	Yes	Yes	Yes
US2021045	Yes	Yes	Yes	Yes
US2021047	Yes	Yes	Yes	Yes
US2021133	Yes	Yes	Yes	Yes
US2021190	Yes	Yes	Yes	Yes
US2021192	Yes	Yes	Yes	Yes
US2021205	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2021216	Yes	Yes	Yes	Yes
US2021217	Yes	Yes	Yes	Yes
US2021220	Yes	Yes	Yes	Yes
US2021226	Yes	Yes	Yes	Yes
US2031086	Yes	Yes	Yes	Yes
US2031096	Yes	Yes	Yes	Yes
US2031097	Yes	Yes	Yes	Yes
US2031104	Yes	Yes	Yes	Yes
US2031105	Yes	Yes	Yes	Yes
US2031106	Yes	Yes	Yes	Yes
US2031107	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2031108	Yes	Yes	Yes	Yes
US2031109	Yes	Yes	Yes	Yes
US2031114	Yes	Yes	Yes	Yes
US2031121	Yes	Yes	Yes	Yes
US2031128	Yes	Yes	Yes	Yes
US2041094	Yes	Yes	Yes	Yes
US2041100	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2041103	Yes	Yes	Yes	Yes
US2041104	Yes	Yes	Yes	Yes
US2041106	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041109	Yes	Yes	Yes	Yes
US2041111	Yes	Yes	Yes	Yes
US2041113	Yes	Yes	Yes	Yes
US2041118	Yes	Yes	Yes	Yes
US2041119	Yes	Yes	Yes	Yes
US2041127	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2041130	Yes	Yes	Yes	Yes
US2041139	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2041145	Yes	Yes	Yes	Yes
US2041150	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041155	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2051057	Yes	Yes	Yes	Yes
US2051059	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2051060	Yes	Yes	Yes	Yes
US2051066	Yes	Yes	Yes	Yes
US2051068	Yes	Yes	Yes	Yes
US2051071	Yes	Yes	Yes	Yes
US2051078	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2051081	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2051092	Yes	Yes	Yes	Yes
US2051093	Yes	Yes	Yes	Yes
US2051094	Yes	Yes	Yes	Yes
US2051095	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051096	Yes	Yes	Yes	Yes
US2051099	Yes	Yes	Yes	Yes
US2051100	Yes	Yes	Yes	Yes
US2051103	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2051105	Yes	Yes	Yes	Yes
US2051107	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2051109	Yes	Yes	Yes	Yes
US2061037	Yes	Yes	Yes	Yes
US2061053	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2061057	Yes	Yes	Yes	Yes
US2061064	Yes	Yes	Yes	Yes
US2061068	Yes	Yes	Yes	Yes
US2071007	Yes	Yes	Yes	Yes
US2071024	Yes	Yes	Yes	Yes
US2071025	Yes	Yes	Yes	Yes
US2071083	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2071090	Yes	Yes	Yes	Yes
US2071099	Yes	Yes	Yes	Yes
US2071101	Yes	No/There was no immunogenicity result at corresponding visit	No/Other study deviation	No/There was no immunogenicity result at corresponding visit; Other study deviation
US2071104	Yes	Yes	Yes	Yes
US2071106	No/There was no immunogenicity result at corresponding visit	Yes	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; Serum collection out of window; Post-baseline COVID-19 infection prior to the visit
US2081003	Yes	Yes	Yes	Yes
US2081009	Yes	Yes	Yes	Yes
US2081020	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2081070	Yes	Yes	Yes	Yes
US2081071	Yes	Yes	Yes	Yes
US2081085	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2081090	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081092	Yes	Yes	Yes	Yes
US2081100	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2081110	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 50 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2081112	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2081118	Yes	Yes	Yes	Yes
US2081123	Yes	Yes	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation	No/Did not receive Vaccination #2; Serum collection out of window; Other study deviation

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2011004	Yes	Yes	Yes	Yes
US2011009	Yes	Yes	Yes	Yes
US2011028	Yes	Yes	Yes	Yes
US2011113	Yes	Yes	Yes	Yes
US2011118	Yes	Yes	Yes	Yes
US2011121	Yes	Yes	Yes	Yes
US2011122	Yes	Yes	Yes	Yes
US2011128	Yes	Yes	Yes	Yes
US2011139	Yes	Yes	Yes	Yes
US2011149	Yes	Yes	Yes	Yes
US2011159	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2011162	No/There was no immunogenicity result at baseline	No/There was no immunogenicity result at baseline	No/Not in Full Analysis Set	No/Not in Full Analysis Set
US2021003	Yes	Yes	Yes	Yes
US2021007	Yes	Yes	Yes	Yes
US2021011	Yes	Yes	Yes	Yes
US2021031	Yes	Yes	Yes	Yes
US2021114	Yes	Yes	Yes	Yes
US2021115	Yes	Yes	Yes	Yes
US2021186	Yes	Yes	Yes	Yes
US2021208	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2021211	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2021214	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2021215	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2021218	Yes	Yes	Yes	Yes
US2021230	Yes	Yes	Yes	Yes
US2021232	Yes	Yes	Yes	Yes
US2021234	Yes	Yes	Yes	Yes
US2031091	Yes	Yes	Yes	Yes
US2031093	Yes	Yes	Yes	Yes
US2031101	Yes	Yes	Yes	Yes
US2031111	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2031112	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2031122	Yes	Yes	Yes	Yes
US2041096	Yes	Yes	Yes	Yes
US2041107	Yes	Yes	Yes	Yes
US2041108	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2041112	Yes	Yes	Yes	Yes
US2041117	Yes	Yes	Yes	Yes
US2041120	Yes	Yes	Yes	Yes
US2041122	Yes	Yes	Yes	Yes
US2041123	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2041125	Yes	Yes	Yes	Yes
US2041126	Yes	Yes	Yes	Yes
US2041131	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation
US2041136	Yes	Yes	Yes	Yes
US2041138	Yes	Yes	Yes	Yes
US2041144	Yes	Yes	Yes	Yes
US2041149	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit	Yes
US2051054	Yes	Yes	Yes	Yes
US2051064	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2051069	Yes	Yes	Yes	Yes
US2051070	Yes	Yes	Yes	Yes
US2051074	Yes	Yes	Yes	Yes
US2051075	Yes	Yes	Yes	Yes
US2051077	Yes	Yes	Yes	Yes
US2051084	Yes	Yes	Yes	Yes
US2051085	Yes	Yes	Yes	Yes
US2051088	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit
US2051097	Yes	Yes	Yes	Yes
US2051101	Yes	Yes	Yes	Yes
US2051102	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2051104	No/There was no immunogenicity result at corresponding visit	No/There was no immunogenicity result at corresponding visit	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set	No/Did not receive Vaccination #2; There was no immunogenicity result at corresponding visit; Not in Full Analysis Set
US2051106	Yes	Yes	Yes	Yes
US2051108	Yes	Yes	Yes	Yes
US2051111	Yes	Yes	Yes	Yes
US2061036	Yes	Yes	Yes	Yes
US2061045	Yes	Yes	Yes	No/Serum collection out of window; Other study deviation
US2061063	Yes	Yes	Yes	Yes
US2071006	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2071013	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation
US2071037	Yes	Yes	Yes	Yes
US2071043	Yes	Yes	Yes	Yes
US2071082	Yes	Yes	Yes	Yes
US2071087	Yes	Yes	Yes	Yes
US2071089	Yes	Yes	Yes	Yes
US2071091	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2071093	Yes	Yes	Yes	Yes
US2071095	Yes	Yes	Yes	Yes

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2071096	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit; Other study deviation	No/Other study deviation
US2081001	Yes	Yes	Yes	Yes
US2081002	Yes	Yes	Yes	Yes
US2081014	Yes	Yes	Yes	Yes
US2081016	Yes	Yes	Yes	Yes
US2081019	Yes	Yes	Yes	Yes
US2081035	Yes	Yes	Yes	Yes
US2081069	Yes	Yes	Yes	Yes
US2081072	Yes	Yes	Yes	Yes
US2081075	Yes	Yes	Yes	Yes
US2081076	Yes	Yes	Yes	Yes

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2081081	Yes	Yes	Yes	Yes
US2081088	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081091	Yes	Yes	Yes	Yes
US2081093	Yes	Yes	Yes	Yes
US2081099	Yes	No/There was no immunogenicity result at corresponding visit	Yes	No/There was no immunogenicity result at corresponding visit
US2081108	Yes	Yes	Yes	Yes
US2081116	Yes	Yes	Yes	Yes
US2081117	Yes	Yes	No/Vaccination #2 out of window; Serum collection out of window; Other study deviation	No/Vaccination #2 out of window; Other study deviation

Program: \Moderna MODMRNA1273P201_U\Primary Analysis\TLF\116020302.sas 19NOV2020 01:25 Database Lock Date: 05NOV2020

Listing 16.2.3.2
Analysis Sets 2
Randomized Set

Cohort 2 (Age >= 55); Vaccination Group: mRNA-1273 100 µg

Subject ID	Full Analysis Set for Neutralizing Antibody from All Lots/Exclusion Reason		Per-Protocol Set for Neutralizing Antibody from All Lots/Exclusion Reason	
	Day 29	Day 57	Day 29	Day 57
US2081120	Yes	Yes	Yes	Yes
US2081121	Yes	Yes	Yes	Yes
US2081129	Yes	Yes	Yes	Yes